Why cutting drug prices is pushing Eli Lilly's stock toward an all-time high

Core Insights - The drug giant is successfully maintaining its competitive edge and is on track to reach a valuation of nearly one trillion dollars, even after significantly reducing the prices of some medications [1] Company Performance - The company has managed to outpace its rivals in the pharmaceutical industry despite the price reductions [1]